team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to updated data from the ongoing EVOLVE-MS-1 Phase 3 clinical trial.
Vumerity, developed by Alkermes in collaboration with Biogen, lowers inflammation associated with MS by reducing levels of reactive oxygen species often called free radicals within nerve cells. This is expected to slow disease progression by reducing nerve cell damage.
It is similar to Tecfidera (dimethyl fumarate), but is expected to cause fewer gastrointestinal (GI) side effects.
E-Mail
MINNEAPOLIS - Stroke survivors who live in neighborhoods with lower socioeconomic status areas with lower household income, education levels and occupational status may have worse recovery three months after a stroke than people who live in neighborhoods with higher socioeconomic status, according to a study published in the April 28, 2021, online issue of
Neurology®, the medical journal of the American Academy of Neurology. The findings applied to people with moderate to severe strokes, not people with mild strokes. People in less advantaged neighborhoods were more likely to have more disability, lower quality of life and more symptoms of depression than people in more advantaged neighborhoods, said study author Lynda D. Lisabeth, PhD, of the University of Michigan in Ann Arbor. Reasons for this could include less access to public spaces in the neighborhood, more noise pollution, less access to support services and lower levels of perceived safety. More research i
COVID-19 update
The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies in which Novartis operates. We continue to take strong actions to help address the pandemic. Our primary concerns remain the health and safety of our associates and patients.
There continues to be COVID-19 related lockdowns and disruptions in several geographies negatively impacting demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. For Sandoz, COVID-19 resulted in a historically weak cough and cold season and softened retail demand. At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Our operations remain stable and cash col
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates.
“We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release.
Investigational MS Drug Evobrutinib Has Potential, Study Shows everydayhealth.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from everydayhealth.com Daily Mail and Mail on Sunday newspapers.